Humana INC 8-K filings

Humana Inc. announced the election of Frederick J. Crawford and Paul J. Smith to its Board of Directors, expanding the board to thirteen members.

Humana Inc. announced solid second quarter 2026 financial results, reporting $7.61 in Adjusted EPS and reaffirming its full-year Adjusted EPS guidance of at least $9.00.

Humana Inc. reaffirms its full-year 2026 guidance for diluted earnings per common share and adjusted earnings per common share during investor meetings.

Humana Inc. announced first quarter 2026 financial results, with Adjusted EPS at the high end of guidance, and affirmed its full-year 2026 adjusted financial outlook.

Humana Inc. shareholders re-elected all ten director nominees and approved the 2026 Stock Incentive Plan at the annual meeting.

Humana Inc. announced the election of Robert S. Field to its Board of Directors, effective after the 2026 Annual Meeting of Stockholders.

Humana Inc. reaffirms its full-year 2026 diluted earnings per common share guidance of at least $8.89 and adjusted earnings per common share of at least $9.00.

Humana Inc. reported a net loss for Q4 2025 and provided full-year 2026 financial guidance anticipating a decline in EPS due to Star Ratings headwinds, while projecting significant Medicare Advantage membership growth.

Humana Inc. announced a key leadership transition with George Renaudin's retirement and the appointment of Aaron Martin, while reaffirming its full-year 2025 earnings guidance.

Humana Inc. reaffirms its full-year 2025 diluted earnings per common share guidance of approximately $12.26 and adjusted earnings per common share guidance of approximately $17.00.

Humana reported Q3 2025 Adjusted EPS of $3.24, affirmed its full-year 2025 Adjusted EPS guidance of approximately $17.00, and improved its individual Medicare Advantage membership decline outlook.

Humana Inc. reaffirms its 2025 earnings guidance while outlining a strategy to improve Medicare Advantage Star Ratings for 2027, despite lower 2026 ratings.

Humana Inc. announced it will reaffirm its full-year 2025 diluted EPS guidance of approximately $13.77 and adjusted EPS of $17.00 during upcoming investor meetings.

Humana reported solid second-quarter 2025 financial results, raising its full-year adjusted earnings per share and consolidated revenue guidance, despite a revised outlook for individual Medicare Advantage membership decline.

Humana Inc. announced it will reaffirm its full-year 2025 diluted and adjusted earnings per share guidance during upcoming investor and analyst meetings.

Humana Inc. has entered into a new $5.0 billion unsecured revolving credit agreement, significantly increasing its borrowing capacity and replacing previous facilities.

Humana reported first quarter 2025 financial results, with adjusted EPS ahead of expectations and reaffirmed its full-year adjusted EPS guidance of approximately $16.25.

Humana Inc. held its annual meeting of stockholders on April 17, 2025, and all proposals, including the election of directors, ratification of the accounting firm, and executive compensation, were approved.

Humana Inc. has entered into an underwriting agreement to issue and sell $250 million in aggregate principal amount of its 5.375% Senior Notes due 2031.

Humana successfully closed a $1.25 billion public offering of senior notes to refinance debt and for general corporate purposes.

Humana reaffirms its FY 2025 earnings guidance during investor meetings, projecting approximately $15.88 in diluted EPS and $16.25 in adjusted EPS.

Humana reports a net loss for Q4 2024 but reaffirms its FY 2025 EPS guidance, anticipating a significant decline in Medicare Advantage membership.

Humana Inc. has announced that Susan Diamond will transition from her role as Chief Financial Officer, with Celeste Mellet appointed as her successor, effective January 11, 2025.

Humana reported strong third-quarter results, exceeding expectations and raising its full-year adjusted EPS guidance to at least $16.00.

Humana Inc. has elected Gordon Smith, a former executive at JPMorgan Chase & Co., to its Board of Directors, increasing the board size to twelve members.

Humana reports a significant drop in its Medicare Advantage Star Ratings for 2025, with only 25% of members in 4-star or higher plans, down from 94% in 2024, impacting future bonus payments.

Humana reaffirms its full-year 2024 earnings guidance of approximately $12.81 per share diluted EPS and $16.00 per share adjusted EPS during investor meetings.

Humana reported second quarter earnings, revised its full-year GAAP EPS guidance downward, but affirmed its adjusted EPS guidance and increased its Medicare Advantage membership growth forecast.

Humana Inc. has entered into a new $2.1 billion revolving credit agreement and amended an existing $2.5 billion agreement, increasing its borrowing capacity.

Humana Inc. reaffirms its full-year 2024 earnings guidance of approximately $13.93 diluted EPS and $16.00 adjusted EPS during investor meetings.